Author/Authors :
Niina Aaltonen، نويسنده , , Juha R. Savinainen، نويسنده , , Casandra Riera Ribas، نويسنده , , Jani R?nkk?، نويسنده , , Anne Kuusisto، نويسنده , , Jani Korhonen، نويسنده , , Dina Navia-Paldanius، نويسنده , , Jukka H?yrinen، نويسنده , , Piia Takabe، نويسنده , , Heikki K?sn?nen، نويسنده , , Tatu Pantsar، نويسنده , , Tuomo Laitinen، نويسنده , , Marko Lehtonen، نويسنده , , Sanna Pasonen-Sepp?nen، نويسنده , , Antti Poso، نويسنده , , Tapi، نويسنده ,
Abstract :
Monoacylglycerol lipase (MAGL) terminates the signaling function of the endocannabinoid, 2-arachidonoylglycerol (2-AG). During 2-AG hydrolysis, MAGL liberates arachidonic acid, feeding the principal substrate for the neuroinflammatory prostaglandins. In cancer cells, MAGL redirects lipid stores toward protumorigenic signaling lipids. Thus MAGL inhibitors may have great therapeutic potential. Although potent and increasingly selective MAGL inhibitors have been described, their number is still limited. Here, we have characterized piperazine and piperidine triazole ureas that combine the high potency attributable to the triazole leaving group together with the bulky aromatic benzodioxolyl moiety required for selectivity, culminating in compound JJKK-048 that potently (IC50 < 0.4 nM) inhibited human and rodent MAGL. JJKK-048 displayed low cross-reactivity with other endocannabinoid targets. Activity-based protein profiling of mouse brain and human melanoma cell proteomes suggested high specificity also among the metabolic serine hydrolases.